Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Southampton
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Southampton, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2015 Manchester 668 Birmingham 478 Glasgow 437 Cambridge 425
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AbbVie11 Janssen Research & Development, LLC11 AstraZeneca10 Novartis Pharmaceuticals8 Eli Lilly and Company7
Site city
London2015 Manchester668 Birmingham478 Glasgow437 Cambridge425
All 429 cities
Target enrolment
to

Trials with a site in Southampton

199 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Not yet open
Zoll Medical Corporation
Not applicable
800
Southampton
2026-10-01
Recruiting
A Study in Adults With Geographic Atrophy
NCT07606365Geographic Atrophy
DrugSTL303
Sitala Bio LTD
Phase 2
300
London, Southampton, Leicester, Newcastle upon Tyne
2026-09-11
Recruiting
ModernaTX, Inc.
Phase 1
375
Manchester, Southampton, Norwich, Birmingham, London, Newcastle
2026-08-11
Recruiting
AstraZeneca
Phase 3
670
London, Middlesbrough, Southampton, Truro
2026-05-04
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
DrugRituximab
Eli Lilly and Company
Phase 1
460
London, Nottingham, Plymouth, Southampton
2026-04-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
Cambridge, Edinburgh, Glasgow, Leicester, Withington, Birmingham, Cardiff, Southampton
2026-04-09
Recruiting
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
ADARx Pharmaceuticals, Inc.
Phase 3
90
Cambridge, Cardiff, London, Southampton
2026-04-02
Recruiting
Renaissance Pharma Ltd.
Phase 2/3
144
Southampton, Sutton
2026-03-30
Recruiting
AIRNA Corporation
Phase 1
54
Cambridge, London, Southampton
2026-03-17
Recruiting
Novartis Pharmaceuticals
Phase 2
272
Bristol, London, Newcastle upon Tyne, Southampton
2026-03-09
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Bath, Cambridge, Greater London, Newcastle upon Tyne, Peterborough, Reading, Southampton, Stoke-on-Trent
2026-03-05
Recruiting
Eli Lilly and Company
Phase 2
465
Chertsey, Doncaster, Eastbourne, Glasgow, London, Manchester, Milton Keynes, Southampton
2026-02-13
Recruiting
Eli Lilly and Company
Phase 3
300
Aberdeen, Birmingham, Bristol, Cambridge, Cardiff, Oxford, Southampton
2026-02-05
Active, closed
Hoffmann-La Roche
Phase 1
6
London, Southampton, Glasgow
2026-01-27
Recruiting
AbbVie
Phase 2
165
Cambridge, Edinburgh, London, Southampton, Norwich
2026-01-23
Recruiting
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT07096778Multiple Myeloma Refractory, Multiple Myeloma in Relapse
DrugsPomalidomide·Dexamethasone
CellCentric Ltd.
Phase 2
100
Withington, Sutton, Cardiff, Bebington, Edinburgh, London, Oxford, Southampton
2026-01-22
Recruiting
Eli Lilly and Company
Phase 3
150
Birmingham, Cambridge, Cardiff, Glasgow, London, Oxford, Southampton
2026-01-12
Recruiting
Contineum Therapeutics
Phase 2
324
Leicester, London, Southampton, Edinburgh, Perth, Birmingham
2026-01-08
Recruiting
Insmed Incorporated
Phase 3
344
London, Sheffield, Bath, Belfast, Glasgow, Salford, Southampton
2026-01-07
By invitation
Medtronic
Observational
2,000
Liverpool, London, Southampton
2026-01-07
Recruiting
Pfizer
Phase 3
32,500
Newquay, Exeter, Plymouth, Torquay, Preston, Glasgow, Southampton, Blackpool
2025-12-10
Recruiting
Boehringer Ingelheim
Phase 3
120
Birmingham, Bristol, Glasgow, Liverpool, London, Newcastle upon Tyne, Nottingham, Southampton
2025-12-09
Recruiting
Syndax Pharmaceuticals
Phase 3
468
Oxford, Aberdeen, Derby, Lincoln, London, Southampton, Sutton
2025-11-25
Recruiting
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
Crinetics Pharmaceuticals Inc.
Phase 3
141
London, Oxford, Birmingham, Cardiff, Glasgow, Sheffield, Southampton
2025-11-19
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
DrugAvacincaptad Pegol
ONL Therapeutics
Phase 2
324
Gloucester, London, Newcastle, Southampton, Sunderland, York, Belfast
2025-10-28
Recruiting
Alnylam Pharmaceuticals
Phase 1
50
Glasgow, London, Sheffield, Southampton
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
1,100
Blackpool, Chester, Eastbourne, Edinburgh, Glasgow, London, Manchester, Southampton
2025-10-15
Recruiting
ImmunityBio, Inc.
Phase 3
507
Belfast, Truro, Bodelwyddan, Cardiff, London, Southampton, Edinburgh, Guildford
2025-10-01
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
London, Southampton, Salford, Bristol, High Wycombe, Kirkcaldy
2025-09-22
Recruiting
Sanofi
Phase 4
218
Dundee, Newcastle upon Tyne, Southampton, Leicester, Bradford, Sheffield
2025-09-22
Recruiting
Sanofi
Phase 3
942
Milton Keynes, London, Southampton, Salford, Chertsey, Reading, Rotherham
2025-09-17
Recruiting
Janssen Research & Development, LLC
Phase 3
220
Cottingham, London, Southampton, Stevenage, Surrey
2025-09-10
Recruiting
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc.
Phase 3
90
Guildford, Cambridge, Cardiff, London, Southampton
2025-08-28
Recruiting
Pfizer
Phase 3
6,000
Bristol, London, Manchester, Truro, Southampton, Oxford, Shropshire, Leeds
2025-08-25
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
153
Birmingham, Sheffield, Southampton
2025-08-21
Recruiting
Takeda
Phase 3
150
Leicester, Southampton, Southwark, Liverpool, Glasgow, Stoke-on-Trent, Leeds, London
2025-08-14
Recruiting
BioNTech SE
Phase 1/2
1,438
Birmingham, Cardiff, Glasgow, Liverpool, London, Manchester, Newcastle upon Tyne, Southampton
2025-08-12
Recruiting
Novartis Pharmaceuticals
Phase 2
407
Edinburgh, Oxford, Aberdeen, London, Newcastle upon Tyne, Salford, Southampton
2025-08-07
Active, closed
UK ENcorafenib and BInimetinib Real-world Study in Melanoma
NCT07022457Metastatic Melanoma, BRAF V600 Mutation Positive
DrugsBinimetinib·Encorafenib
Pierre Fabre Ltd
Observational
50
Westcliff-on-Sea, Birmingham, Cambridge, Coventry, London, Preston, Southampton
2025-07-31
Recruiting
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
NCT07144137Geographic Atrophy Secondary to Age-related Macular Degeneration
Complement Therapeutics
Observational
75
Gloucester, London, Southampton, Sunderland, Belfast, Frimley, Manchester
2025-07-30
Recruiting
Kiniksa Pharmaceuticals International, plc
Phase 2/3
325
London, Southampton
2025-07-25
Recruiting
Pharmazz, Inc.
Phase 3
514
Bury, London, Southampton, Wolverhampton, Harrow, Newcastle, Stoke-on-Trent
2025-07-24
Recruiting
Pfizer
Phase 3
714
Truro, Sheffield, Southampton, Northwood, London, Taunton, Ipswich, Manchester
2025-07-23
Recruiting
Merck Sharp & Dohme LLC
Phase 2
340
Aberdeen, Edinburgh, Southampton, London, Oxford, Bath, Birmingham
2025-07-16
Recruiting
Galderma R&D
Observational
1,000
London, Southampton, Watford, Kings Lynn, Harrogate, Sheffield, Birmingham, Leeds
2025-07-14
Recruiting
Novo Nordisk A/S
Phase 2
200
Birmingham, High Wycombe, London, Middlesbrough, Southampton
2025-06-30
Recruiting
Novo Nordisk A/S
Phase 2
200
Birmingham, High Wycombe, London, Middlesbrough, Southampton
2025-06-27
Active, closed
DBV Technologies
Phase 3
480
Glasgow, Leicester, London, Manchester, Sheffield, Southampton
2025-06-24
Active, closed
Calluna Pharma AS
Phase 2
150
Birmingham, Edinburgh, Leeds, London, Manchester, Newcastle upon Tyne, Oxford, Southampton
2025-06-20
Recruiting
Step Pharma, SAS
Phase 2
50
Sheffield, Cardiff, London, Oxford, Southampton
2025-06-18
Recruiting
Neurocrine Biosciences
Phase 3
200
London, Salford, Sheffield, Southampton
2025-05-30
Recruiting
Eikon Therapeutics
Phase 2/3
740
Belfast, London, Southampton
2025-05-22
Active, closed
FARAPULSE Workflow Assessment Registry
NCT06656884Atrial Fibrillation (AF)
Boston Scientific Corporation
Observational
524
Bournemouth, Cambridge, Leicester, Newcastle upon Tyne, Southampton
2025-05-06
Recruiting
AstraZeneca
Phase 1
72
Glasgow, London, Southampton
2025-05-01
Recruiting
Neurocrine Biosciences
Phase 3
850
Southampton, Sheffield, London, Manchester
2025-04-16
Active, closed
Janssen Research & Development, LLC
Phase 3
752
Dudley, Harrow, Kings Lynn, London, Reading, Salford, Southampton, Wakefield
2025-04-15
Recruiting
BeOne Medicines
Phase 3
250
Aberdeen, Birmingham, Bournemouth, London, Southampton
2025-04-10
Active, closed
Novartis Pharmaceuticals
Phase 3
565
Leeds, Bristol, Cardiff, London, Southampton
2025-03-20
Recruiting
Immunovant Sciences GmbH
Phase 2
162
Bristol, Glasgow, Salford, Southampton
2025-03-18
Recruiting
Novartis Pharmaceuticals
Phase 3
9
Southampton
2025-02-28
Active, closed
iOnctura
Phase 2
85
Northwood, Bebington, Glasgow, London, Southampton
2025-02-27
Recruiting
Takeda
Phase 3
171
Leicester, Southampton, Southwark, Liverpool, Glasgow, Stoke-on-Trent, Leeds, London
2025-02-27
Active, closed
BioMarin Pharmaceutical
Phase 1
6
Edinburgh, London, Southampton
2025-02-21
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Derriford, London, Oxford, Southampton
2025-01-30
Active, closed
argenx
Phase 3
631
Southampton, Sheffield, Cannock
2025-01-15
Recruiting
Immatics US, Inc.
Phase 3
360
Cambridge, Glasgow, London, Manchester, Oxford, Southampton
2025-01-14
Recruiting
Cytokinetics
Phase 3
1,800
Harefield, Southampton, Glasgow, Basingstoke, Cottingham, Dudley, Dundonald, Swindon
2024-12-19
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 3
50
Cardiff, Leeds, Liverpool, London, Southampton
2024-11-21
Active, closed
Longboard Pharmaceuticals
Phase 3
367
Cardiff, Newcastle upon Tyne, Southampton, Glasgow, Birmingham, London
2024-11-11
Active, closed
Sanofi Pasteur, a Sanofi Company
Phase 1/2
750
Exeter, London, Southampton
2024-11-05
Active, closed
AstraZeneca
Phase 3
310
Belfast, Liverpool, London, Southampton
2024-09-30
Active, closed
Merus B.V.
Phase 3
699
Cambridge, Cardiff, London, Manchester, Newcastle upon Tyne, Northwood, Southampton, Sutton
2024-09-25
Active, closed
argenx
Phase 3
141
Brighton, Glasgow, Leeds, London, Southampton
2024-09-18
Active, closed
Novo Nordisk A/S
Phase 4
500
Birmingham, Bristol, Leeds, Liverpool, London, Sheffield, Southampton
2024-09-17
Recruiting
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
NCT06547840Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Triple -Negative Breast Cancer
Epsilogen Ltd
Phase 1
45
Bristol, Edinburgh, Leeds, London, Southampton
2024-09-03
Active, closed
Celgene
Phase 2
95
Southampton, Canterbury, Edinburgh, Nottingham
2024-08-30
Recruiting
Prevail Therapeutics
Phase 1
124
Southampton, Oxford
2024-08-27
Recruiting
AbbVie
Phase 3
675
Plymouth, London, Southampton, Glasgow, Manchester, Newcastle upon Tyne
2024-08-19
Recruiting
Eli Lilly and Company
Phase 1
48
London, Sheffield, Southampton
2024-08-15
Recruiting
AstraZeneca
Phase 3
1,018
London, Newcastle upon Tyne, Norwich, Nottingham, Plymouth, Southampton
2024-08-07
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Inverness, Swinton, Birmingham, London, Southampton
2024-07-31
Active, closed
Ferrer Internacional S.A.
Phase 2
241
Cambridge, London, Newcastle, Southampton
2024-07-23
Recruiting
GlaxoSmithKline
Phase 3
150
Bradford, London, Southampton
2024-07-19
Recruiting
LDR Médical SAS
Observational
100
London, Newcastle upon Tyne, Southampton
2024-07-18
Active, closed
Versius Paediatrics Study
NCT06539442Robotic Surgical Procedures in Pediatric Urology
CMR Surgical Ltd
Not applicable
150
London, Manchester, Southampton
2024-07-08
Active, closed
Sanofi
Phase 2
185
Dundee, Wythenshawe, Exeter, Southampton, Coventry
2024-06-20
Recruiting
Beam Therapeutics Inc.
Phase 1/2
192
Birmingham, London, Southampton
2024-06-19
Recruiting
Oncoinvent Solutions AS
Phase 2
114
London, Southampton
2024-06-15
Recruiting
LEO Pharma
Phase 3
195
Lincoln, London, Sheffield, Southampton
2024-06-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Cambridge, Exeter, Doncaster, Huddersfield, London, Southampton, Oxford, Bristol
2024-06-05
Recruiting
Société des Produits Nestlé (SPN)
Not applicable
380
Crowborough, Southampton
2024-05-24
Active, closed
Hoffmann-La Roche
Phase 2
256
Chertsey, Edinburgh, London, Manchester, Southampton
2024-05-02
Recruiting
Janssen Research & Development, LLC
Phase 3
641
Bristol, London, Newcastle upon Tyne, Sheffield, Southampton, Sutton
2024-04-18
Active, closed
Janssen Research & Development, LLC
Phase 3
272
London, Salford, Southampton, Stevenage
2024-04-09
Recruiting
Corbus Pharmaceuticals Inc.
Phase 1/2
348
Birmingham, Cambridge, Cardiff, Leeds, London, Manchester, Metropolitan Borough of Wirral, Southampton
2024-04-01
Recruiting
Italfarmaco
Phase 3
220
Belfast, Boston, London, Milton Keynes, Oxford, Southampton
2024-03-26
Recruiting
AstraZeneca
Phase 3
100
Birmingham, Bristol, Liverpool, London, Manchester, Southampton
2024-03-14
By invitation
Sarepta Therapeutics, Inc.
Phase 1/2
78
London, Nottingham, Southampton
2024-03-04
Active, closed
ReCode Therapeutics
Phase 2
128
Birmingham, Cambridge, Leeds, London, Nottingham, Southampton
2024-02-01
Active, closed
DualityBio Inc.
Phase 3
541
Truro, London, Southampton, Manchester, Maidstone, Middlesex, Nottingham, Bath
2024-01-18
Active, closed
Regeneron Pharmaceuticals
Observational
11
Southampton, London
2024-01-17
Active, closed
Janssen Research & Development, LLC
Phase 3
774
London, Reading, Salford, Southampton
2024-01-17
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
100
Cardiff, Glasgow, Liverpool, London, Newcastle upon Tyne, Nottingham, Southampton
2024-01-16
Recruiting
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
NCT06190899mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease
DrugsGedatolisib·Darolutamide
Celcuity Inc
Phase 1/2
54
Cambridge, Southampton, Sutton
2024-01-01
Recruiting
Bristol-Myers Squibb
Phase 1/2
460
Southampton, Manchester, Edinburgh
2023-12-29
Recruiting
Biogen
Observational
20
London, Salford, Southampton, Nottingham, Oswestry, Sheffield, Newcastle upon Tyne, Birmingham
2023-12-15
Active, closed
Gilead Sciences
Phase 2
176
Bury, Cambridge, London, Norwich, Southampton
2023-12-05
Recruiting
Chiesi Farmaceutici S.p.A.
Phase 1/2
45
Cambridge, Dundee, Edinburgh, Glasgow, Leeds, London, Manchester, Southampton
2023-11-29
Active, closed
BeOne Medicines
Phase 3
652
Bournemouth, Canterbury, Headington, Leeds, Liverpool, London, Norwich, Southampton
2023-11-11
Active, closed
Pfizer
Phase 3
1,571
Isleworth, Southampton, London
2023-11-08
Active, closed
AbbVie
Phase 3
122
Sheffield, London, Southampton, Birmingham
2023-11-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Bristol, Cambridge, Exeter, Doncaster, Huddersfield, London, Southampton, West Midlands
2023-10-25
Recruiting
W.L.Gore & Associates
Not applicable
244
Canterbury, London, Southampton
2023-10-17
Active, closed
Janssen Research & Development, LLC
Phase 3
311
Harrow, Salford, Southampton
2023-10-12
Active, closed
Bristol-Myers Squibb
Phase 3
774
Southampton, Wolverhampton, Birmingham, Cannock
2023-09-11
By invitation
CSL Behring
Observational
56
London, Cambridge, Southampton
2023-08-30
Active, closed
AbbVie
Phase 3
1,014
Bretton, London, Southampton, Northampton, Londonderry, Luton, Portsmouth
2023-07-25
Active, closed
Novartis Pharmaceuticals
Phase 3
100
Peterborough, Manchester, Southampton
2023-07-11
Active, closed
Novo Nordisk A/S
Phase 3
212
Birmingham, Bristol, Leeds, Liverpool, Southampton
2023-07-07
Active, closed
Alumis Inc
Phase 2
408
Leeds, London, Southampton
2023-06-26
Active, closed
AbbVie
Phase 3
1,328
London, Southampton, Coventry, Leeds, Bristol, Salford
2023-06-21
Active, closed
Alfasigma S.p.A.
Observational
509
Belfast, Bury, Exeter, Glasgow, London, Norwich, Oxford, Southampton
2023-06-12
Active, closed
OncoSil Medical Limited
Phase 2
88
London, Manchester, Newcastle upon Tyne, Southampton
2023-04-26
Recruiting
Regeneron Pharmaceuticals
Phase 1
107
Truro, Southampton, Edinburgh, Manchester
2023-04-20
Active, closed
Thoraflex Hybrid and Relay Extension Post-Approval Study
NCT05639400Thoracic Diseases, Aortic Aneurysm, Aortic Dissection, Thoracic Aortic Aneurysm
Vascutek Ltd.
Observational
352
Bristol, Oxford, Southampton
2023-03-17
Recruiting
Vega Therapeutics, Inc
Phase 1/2
116
Birmingham, Southampton, London, Whitechapel
2023-03-16
Active, closed
AbbVie
Phase 3
520
Cheltenham, London, Northwood, Southampton, Sutton, Manchester, Swansea
2023-03-15
Active, closed
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
DrugsTovorafenib·Carboplatin
Day One Biopharmaceuticals, Inc.
Phase 3
418
Birmingham, Leeds, Liverpool, Manchester, Newcastle upon Tyne, Oxford, Southampton, Belfast
2023-02-27
Active, closed
DBV Technologies
Phase 3
600
London, Manchester, Sheffield, Southampton
2023-02-21
Active, closed
Kite, A Gilead Company
Phase 3
300
Birmingham, Southampton
2023-02-10
Active, closed
Hoffmann-La Roche
Phase 2
301
Birmingham, Cambridge, Leeds, London, Oxford, Southampton
2023-02-03
By invitation
BioMarin Pharmaceutical
Observational
172
Cambridge, Glasgow, London, Oxford, Southampton
2023-01-01
Active, closed
AriBio Co., Ltd.
Phase 3
1,535
Cambridge, Cornwell, Exeter, London, Motherwell, Oxford, Southampton
2022-12-23
Active, closed
Kite, A Gilead Company
Phase 3
231
Birmingham, Cambridge, London, Manchester, Oxford, Southampton, Sutton
2022-09-22
Recruiting
ModernaTX, Inc.
Phase 1/2
361
Preston, Glasgow, Birmingham, London, Manchester, Oxford, Southampton
2022-09-01
Active, closed
Biogen
Phase 2
416
London, Manchester, Southampton, Oxford, Sheffield, Motherwell, Birmingham, Bristol
2022-08-24
Recruiting
Ionis Pharmaceuticals, Inc.
Phase 1
40
London, Oxford, Salford, Southampton
2022-07-21
Recruiting
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
NCT05413850Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms
Blue Earth Therapeutics Ltd
Phase 1/2
82
Bristol, Glasgow, London, Middlesbrough, Oxford, Sheffield, Southampton
2022-07-20
Recruiting
First in Human Study of T3P-Y058-739 (T3P)
NCT05120596Advanced Solid Tumor
DrugPembrolizumab
T3 Pharmaceuticals AG
Phase 1/2
100
Glasgow, Leeds, London, Southampton
2022-04-26
Recruiting
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT05131022Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
DrugBexobrutideg
Nurix Therapeutics, Inc.
Phase 1
572
Manchester, Glasgow, Leeds, Liverpool, London, Oxford, Plymouth, Southampton
2022-04-13
Active, closed
AstraZeneca
Phase 3
1,035
Edinburgh, Glasgow, Guildford, Hackensack, London, Manchester, Southampton, Sutton
2022-03-25
Active, closed
BeOne Medicines
Phase 3
799
Glasgow, Greater Manchester, Huddersfield, Inverness, Leeds, London, Plymouth, Southampton
2022-03-10
Active, closed
Novartis Pharmaceuticals
Phase 2
168
London, Southampton
2022-02-17
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
DrugsEylea·Aflibercept
AbbVie
Phase 3
735
Aylesbury, London, Gloucester, Southampton, Oxford, Leeds, Bradford, Bristol
2022-01-13
Active, closed
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
DrugUstekinumab
Janssen Research & Development, LLC
Phase 3
159
Birmingham, Cambridge, London, Sheffield, Southampton
2021-10-18
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
333
Southampton, Birmingham, Belfast, London, Newcastle upon Tyne, Nottingham
2021-09-22
Active, closed
Boston Scientific Corporation
Not applicable
297
Leeds, Liverpool, Manchester, Southampton
2021-07-20
Active, closed
Bristol-Myers Squibb
Phase 3
670
Southampton, Harlow, Stoke-on-Trent
2021-07-13
By invitation
Philips Clinical & Medical Affairs Global
Not applicable
3,212
Southampton, Cardiff, Bournemouth, London
2021-06-17
Active, closed
Hoffmann-La Roche
Phase 3
761
Cambridge, Edinburgh, London, Plymouth, Preston, Sheffield, Southampton, Sutton
2021-05-03
Recruiting
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
DrugsNavtemadlin·Acalabrutinib
Kartos Therapeutics, Inc.
Phase 1/2
84
Leeds, London, Southampton
2021-02-23
Recruiting
BioInvent International AB
Phase 1/2
250
Birmingham, Leicester, London, Manchester, Southampton
2021-01-25
Active, closed
Genmab
Phase 3
483
Birmingham, London, Norwich, Nottingham, Plymouth, Southampton, Sutton, Truro
2021-01-13
Active, closed
UCB Biopharma SRL
Phase 1
19
London, Southampton
2020-11-16
Active, closed
GlaxoSmithKline
Phase 3
302
London, Plymouth, Southampton, Stoke-on-Trent, Sutton
2020-10-01
Active, closed
AbbVie
Phase 3
527
Cambridge, Exeter, Edinburgh, London, Southampton, Stevenage, Glasgow, Nottingham
2020-09-30
Active, closed
GlaxoSmithKline
Phase 3
242
Basingstoke, Glasgow, London, Newcastle upon Tyne, Nottingham, Plymouth, Reading Berkshire, Southampton
2020-07-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Sheffield, London, London-Camden, Southampton, Leeds, Manchester
2020-07-06
Active, closed
Episealer® Knee System IDE Clinical Study
NCT04000659Degenerative Lesion of Articular Cartilage of Knee
Episurf Medical Inc.
Not applicable
13
Coventry, Southampton
2020-06-18
Active, closed
Sanofi
Phase 3
337
Bournemouth, London, Leicester, Southampton
2020-06-16
Recruiting
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
NCT04256317Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
DrugsVenclexta·Azacitidine·Venetoclax
Taiho Oncology, Inc.
Phase 2/3
316
London, Maidstone, Manchester, Oxford, Southampton
2020-05-21
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
886
Glasgow, London, Oxford, Plymouth, Preston, Sheffield, Southampton
2020-03-30
Recruiting
Acurable Ltd.
Observational
200
Sheffield, Southampton
2020-02-19
Recruiting
Amgen
Phase 3
24
Glasgow, Leeds, London, Southampton
2019-12-20
Active, closed
GlaxoSmithKline
Phase 1
118
Leicester, Oxford, Southampton
2019-12-18
Active, closed
Foundry Innovation & Research 1, Limited (FIRE1)
Not applicable
50
Bournemouth, Glasgow, Leicester, London, Portsmouth, Southampton
2019-11-22
Active, closed
RhoVac APS
Phase 2
180
Liverpool, London, Nottingham, Southampton
2019-11-19
Active, closed
Bristol-Myers Squibb
Phase 3
790
Cardiff, Southampton
2019-10-28
Recruiting
GlaxoSmithKline
Phase 1/2
184
Birmingham, Cardiff, Glasgow Strathclyde, London, Manchester, Nottingham, Southampton
2019-10-25
Active, closed
Eli Lilly and Company
Phase 3
30
Bristol, Cambridge, Liverpool, Newcastle upon Tyne, Southampton, London, Sheffield
2019-10-16
Active, closed
SyncAV Post-Market Trial
NCT04100148Congestive Heart Failure
Abbott Medical Devices
Not applicable
1,686
Southampton, Oxford, Brighton
2019-10-03
Active, closed
RECORDATI GROUP
Observational
125
Newcastle upon Tyne, Birmingham, Southampton
2019-09-30
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Bath, Leicester, London, Manchester, Oxford, Southampton, Sutton, Taunton
2019-09-18
Active, closed
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
DrugsVenclexta·Venetoclax
AbbVie
Phase 3
165
Plymouth, Leicester, London, Southampton, Blackpool, Liverpool, Wolverhampton
2019-09-06
Active, closed
Janssen Research & Development, LLC
Phase 2/3
118
Leeds, Liverpool, London, Oxford, Plymouth, Southampton
2019-08-15
Recruiting
Bristol-Myers Squibb
Phase 2
1,500
London, Manchester, Southampton, Maidstone, Northwood, Edinburgh, Glasgow
2019-08-09
Active, closed
Eisai Inc.
Phase 3
1,906
Plymouth, Southampton, Sheffield, Birmingham, Guildford, London
2019-03-27
Active, closed
AstraZeneca
Phase 3
895
Guildford, Manchester, Sheffield, Southampton, Swansea
2018-10-31
Active, closed
AbbVie
Phase 3
1,242
Cambridge, Exeter, Edinburgh, London, Southampton, Barnsley, Liverpool, Newcastle upon Tyne
2018-08-28
Active, closed
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
NCT03625037DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL
DrugEpcoritamab
Genmab
Phase 1/2
666
Manchester, Plymouth, Southampton, Sutton
2018-06-26
Active, closed
AstraZeneca
Phase 3
1,018
Birmingham, Glasgow, Guildford, London, Sheffield, Southampton, Taunton
2018-05-14
Active, closed
Y-mAbs Therapeutics
Phase 2
122
Glasgow, Leeds, Southampton
2018-04-03
Active, closed
Janssen Research & Development, LLC
Phase 3
629
Bristol, London, Manchester, Plymouth, Sheffield, Southampton, Sutton
2018-03-23
Active, closed
Janssen Research & Development, LLC
Phase 2
136
Bath, London, Southampton, Sutton, Truro
2018-03-02
Active, closed
Acerta Pharma BV
Phase 1
12
Birmingham, Bournemouth, Cardiff, Leeds, London, Nottingham, Oxford, Southampton
2018-01-31
Active, closed
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT03767348Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
DrugsVusolimogene Oderparepvec·Opdivo·Nivolumab
Replimune, Inc.
Phase 2
340
Leeds, Oxford, Glasgow, Bebington, London, Southampton
2017-09-20
Active, closed
Acerta Pharma BV
Phase 3
310
Birmingham, Cambridge, Canterbury, Leicester, London, Maidstone, Manchester, Southampton
2017-02-02
Active, closed
AstraZeneca
Phase 1
117
Glasgow, London, Manchester, Southampton
2016-12-28
Active, closed
Geron Corporation
Phase 2/3
289
Leeds, Nottingham, Southampton, Aberdeen
2016-01-12
Active, closed
On-X Life Technologies, Inc.
Observational
510
Blackpool, Hull, London, Oxford, Southampton
2015-11-10
Active, closed
Taiho Oncology, Inc.
Phase 1/2
253
Leicester, Southampton, Oxford, Sutton, Birmingham, Glasgow, London, Manchester
2015-07-14
Active, closed
Acerta Pharma BV
Phase 3
535
Bournemouth, Cambridge, Leeds, Leicester, London, Plymouth, Southampton, Truro
2015-06-26
Active, closed
Acerta Pharma BV
Phase 2
124
Cardiff, Leeds, Leicester, Nottingham, Oxford, Plymouth, Southampton
2015-03-02
Active, closed
Karyopharm Therapeutics Inc
Phase 2
244
Gloucester, Southampton, Sutton, Harrow, Leeds, Cambridge, Liverpool, London
2014-11
Active, closed
Acerta Pharma BV
Phase 2
107
Bournemouth, Leeds, Leicester, London, Oxford, Plymouth, Southampton
2014-09-11
Active, closed
AbbVie
Observational
1,446
Derby, Sheffield, London, Southampton, Glasgow, Carshalton, Aberdeen, Birmingham
2014-08-28
Active, closed
MedImmune LLC
Phase 2
571
Leeds, Leicester, London, Maidstone, Manchester, Metropolitan Borough of Wirral, Plymouth, Southampton
2013-05-17
Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183Atypical Hemolytic-Uremic Syndrome
Alexion Pharmaceuticals, Inc.
Observational
3,000
Cardiff, Exeter, London, Manchester, Newcastle, Southampton, Wales
2013-03-18
Active, closed
Continuum Ceramic on Ceramic Bearing Post Market Clinical Follow-Up Study
NCT03343171Osteoarthritis, Avascular Necrosis, Inflammatory Arthritis, Post-traumatic Arthritis
Zimmer Biomet
Observational
203
Glasgow, Oxford, Southampton
2010-09-15
Rows per page Showing 1–199 of 199
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-uk/city/southampton

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 11 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 199 of those studies with a site in Southampton.

How many clinical trials are recruiting in Southampton?

93 of the 199 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:15 UTC sync. A further 1 have not yet opened recruitment, 100 are active but closed to new participants, and 5 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Southampton), 199 studies
PhaseStudiesRecruitingShare
Phase 3903845.2%
Phase 2371518.6%
Phase 1/219159.5%
Observational1869%
Phase 117118.5%
Not applicable924.5%
Phase 2/3753.5%
Phase 4211%

Most active sponsors

Lead sponsors with the most studies (Southampton)
Lead sponsorStudiesRecruiting
AbbVie112
Janssen Research & Development, LLC113
AstraZeneca105
Novartis Pharmaceuticals84
Eli Lilly and Company76
Bristol-Myers Squibb63
Merck Sharp & Dohme LLC64
Acerta Pharma BV50
GlaxoSmithKline52
Hoffmann-La Roche40
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.